UCB enters strategic partnerships with Parexel and PRA

Thursday, November 17, 2011 10:33 AM

Brussels, Belgium-based UCB has entered into strategic partnerships with Parexel and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis.

"Our strategic partnerships with Parexel and PRA will improve efficiency and cost effectiveness, as well as increase opportunity for innovation, collaboration, and the continuous improvement of quality and services – helping us to deliver new medicines to patients worldwide. By putting these new arrangements in place, Parexel and PRA essentially become integrated members of our study teams," said Iris Loew-Friedrich, executive vice president and chief medical officer of UCB.

"Through the partnership, UCB will receive the benefits of Parexel’s proven clinical processes through all phases of development, which are supported by its market-leading eClinical technology platform. UCB will also leverage Parexel’s consulting expertise in regulatory affairs and commercialization," said Josef von Rickenbach, chairman and CEO of Parexel International.

 "Working as an extension of UCB’s development team, we have the opportunity to execute trials in an innovative and transformational way. While our medical expertise includes significant experience in CNS indications, we also provide a full suite of services for clinical studies across all phases and therapeutic areas. With eClinical solutions, advanced technological tools and finely tuned systems we can achieve seamless delivery and operational transparency throughout our organization,"  noted Colin Shannon, president and CEO of PRA.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs